Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oryzon Genomics (BME: ORY)

Last close As at 01/11/2024

EUR1.64

▲ −0.01 (−0.61%)

Market capitalisation

EUR107m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Update

Oryzon Genomics — Q3 results recap key upcoming inflection points

Healthcare | Flash note

Oryzon Genomics — FDA aligns on Phase III BPD plans

Healthcare | Update

Oryzon Genomics — Final PORTICO data reaffirms potential in BPD

Healthcare | Flash note

Oryzon Genomics — First patient dosed in new AML combination study
testalize-me-0jE8ynV4mis-unsplash
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (9.2) (11.5) (18.2)
Relative (7.6) (16.1) (36.8)
52 week high/low €2.2/€1.6

Financials

Oryzon has reported its Q324 results, the highlight of which was the borderline personality disorder (BPD) programme, with the final Phase IIb PORTICO data demonstrating vafidemstat’s potential to offer meaningful results in a condition with no approved drugs currently. A further boost was the positive FDA feedback for Phase III, and the next step will be the submission of a full trial protocol for PORTICO-2 (expected in Q125). Oryzon also made strides in strengthening its intellectual property (IP) profile, extending vafidemstat’s patent protection up to at least 2040. In oncology, the first patient was dosed in the investigator-initiated Phase Ib study of iadademstat with venetoclax and azacitidine in acute myeloid leukaemia (AML). For FRIDA (iadademstat with gilteritinib in AML), the strategic priority in oncology, the next update will be at EHA 2025. Our valuation adjusts to €796m or €12.3/share (from €775m or €12.1/share).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.6) (7.49) N/A N/A
2023A 14.2 (4.4) (6.1) (5.65) N/A N/A
2024E 7.6 (4.0) (4.9) (3.13) N/A N/A
2025E 40.5 26.8 25.5 43.90 3.8 3.6

Research

testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — FDA aligns on Phase III BPD plans

Update

Healthcare

Oryzon Genomics — Final PORTICO data reaffirms potential in BPD

Healthcare

Update

Oryzon Genomics — Q3 results recap key upcoming inflection points
View All

Further insights

insight

Epigenetics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free